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International migration has changed the epidemiologic 
patterns of Chagas disease. Recently, 2 cases of Chagas 
disease transmitted from Latin American women to their 
newborns were diagnosed in Geneva, Switzerland. A retro-
spective study to detect Chagas disease showed a preva-
lence of 9.7% among 72 Latin American women tested dur-
ing pregnancy in Switzerland.
C
hagas disease, a zoonotic infection caused by Try-
panosoma cruzi, is the most important endemic para-
sitic infection in Mexico and Central and South America 
because of the number of persons who become ill or die 
from this disease (1). An estimated 8–10 million persons 
are infected, and ≈14,000 persons die each year from Cha-
gas disease (1,2). Historically, transmission by triatomine 
vectors has been the most common source of infection; 
however, the populations affected, transmission routes, 
and geographic distribution of Chagas disease cases have 
been greatly modiﬁ  ed by urbanization and international 
migration. An estimated 14 million people from countries 
in which Chagas disease is endemic have moved to North 
America, Europe, Japan, and Australia. The number of per-
sons currently infected by T. cruzi is probably >100,000 in 
the United States and >6,000 in Spain (2).
In Europe, vertical, transfusional, and transplanta-
tional routes have accounted for all cases of transmission. 
The risk for vertical transmission from an infected mother 
to her newborn is ≈5% (3). Vertical transmission is likely 
to go undetected in Europe because of lack of screening 
programs for at-risk pregnant women, who are usually in 
the long-lasting, chronic, asymptomatic phase of the dis-
ease and are unaware of their infection. An estimated 2,000 
babies may have been born with T. cruzi infection in North 
America in recent years, and 2 cases of vertical transmission 
were recently reported from Spain (4–6). We report 2 ad-
ditional cases of congenital infection with T. cruzi, detected 
in 2001 and 2006, at the Geneva University Hospitals in 
Switzerland. Subsequently, we conducted a retrospective 
serologic survey of pregnant Latin American immigrants 
to assess the potential for vertical transmission of Chagas 
disease in Switzerland.
The Cases
In 2001, a 31-year-old woman from Santa Cruz, Boliv-
ia, delivered a 2,860-g, full-term, apparently healthy baby 
at the Geneva University Hospitals after an uncomplicated 
pregnancy. Like most undocumented immigrants recently 
arrived in Switzerland, she had received no medical su-
pervision during her pregnancy. She stated that a blood 
test for T. cruzi, conducted in Bolivia, had been negative. 
Macroscopic examination of the fetal side of the placenta 
showed a 3.5-cm, subchorial, liquid-ﬁ  lled cyst (Figure 1). 
Histopathologic examination showed disseminated chorio-
amnionitis and associated funiculitis with large numbers of 
nonﬂ  agellated parasites. A recent infection with Toxoplas-
ma gondii was ruled out by serologic testing. Congenital 
T. cruzi infection was conﬁ  rmed by a positive blood mi-
croscopic examination for the infant, a positive serologic 
test result for the mother (immunoﬂ  uorescence assay using 
killed T. cruzi parasites, Swiss Tropical Institute, Basel, 
Switzerland), and a positive blood PCR with TCZ1/TCZ2 
primers for both the mother and the newborn. Electrocar-
diogram and echocardiogram of the newborn showed no ab-
normalities. The newborn received nifurtimox (10 mg/kg/d 
for 60 days) without notable adverse effects. Parasitemia 
became undetectable at the end of treatment, and serologic 
test result at 1 year of age was negative. The mother refused 
to be treated, claiming that she was feeling ﬁ  ne.
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Figure 1. Fetal side of the placenta from Latin American pregnant 
woman who delivered her baby at Geneva University Hospitals, 
Geneva, Switzerland. A macroscopic subchorial liquid-ﬁ  lled  cyst 
can be seen near the umbilical cord insertion.In 2006, a 25-year-old woman arrived in Switzerland 
from Santa Cruz, Bolivia, when she was 5 months preg-
nant. She delivered a 2,480-g, premature but healthy baby 
at 34 weeks’ gestation at the Geneva University Hospitals. 
After discharge, histopathologic examination of the placen-
ta showed funiculitis and chorioamnionitis with clusters of 
nonﬂ  agellated parasites. The mother had not been previ-
ously tested for T. cruzi but related that her father had died 
of Chagas disease–related heart complications. T. cruzi se-
rologic testing by immunoﬂ  uorescence was positive for the 
mother, and blood microscopic examination and PCR were 
positive for the newborn, conﬁ  rming vertical transmission. 
Electrocardiogram and echocardiogram of the baby showed 
no abnormalities. The newborn began a 60-day course of 
nifurtimox (10 mg/kg/d) at 20 weeks of age and had no ad-
verse effects. Blood PCR and serologic testing at 5 and 26 
weeks after treatment was started, respectively, produced 
negative results. The mother was treated with nifurtimox 
after completion of breast-feeding and showed good toler-
ance to the drug.
The Study
In response to these 2 cases, in 2007, a retrospective 
serologic survey for T. cruzi infection was performed on 
stored serum samples from 72 undocumented pregnant 
Latin American women who had received prenatal care at 
the Geneva University Hospitals during the previous year. 
Median age was 30 years (range 20–43), and countries of 
origin were Bolivia (n = 30), Brazil (n = 22), Peru (n = 6), 
Ecuador (n = 5), Colombia (n = 4), Chile (n = 2), Honduras 
(n = 1), and unknown (n = 2). Serum samples were tested 
by IFA using T. cruzi parasites from in vitro culture (Swiss 
Tropical Institute). No conﬁ  rmatory test was available. Of 
the 72 samples, 7 (9.7%) were positive, most from Bolivian 
women (n = 5). The seroprevalence among Bolivian wom-
en was 16.6% (5/30), consistent with prevalence found by 
similar surveys conducted recently in Bolivian maternity 
hospitals (7). Limitations of the study include the small 
number of samples tested and lack of a conﬁ  rmatory test as 
recommended by the World Health Organization.
Conclusions
Only a small number of congenital cases of Chagas dis-
ease have been reported in countries in which this infection 
is nonendemic. The absence of routine screening programs 
for Chagas disease in pregnant women and newborns at 
risk most likely explains this low number, but other factors 
may be involved. Chagas disease affects immigrants, who 
frequently lack legal status and therefore experience dif-
ﬁ  culties (e.g., fear of deportation and ﬁ  nancial and admin-
istrative constraints) in accessing quality healthcare dur-
ing pregnancy. In Switzerland, undocumented immigrant 
women have poor access to medical supervision during 
pregnancy, so most consult a physician late in pregnancy 
or at time of delivery (8). Chagas disease is rare in Europe, 
and healthcare workers may simply not search for it, re-
sulting in missed opportunities to diagnose the disease. In 
addition, up to two thirds of infected newborns are asymp-
tomatic at birth, so congenital infection may go undetected 
if not actively sought.
Systematic screening of pregnant women at risk is 
likely to be beneﬁ  cial in several ways. Treatment of in-
fected mothers after completion of breast-feeding may re-
duce the risk for vertical transmission during subsequent 
pregnancies. Treatment of young women at the chronic, 
indeterminate stage of infection is likely to lower their risk 
for developing cardiac complications (9). Early screening 
and treatment of infected newborns are associated with 
high cure rates (10). Older children of mothers with newly 
diagnosed Chagas disease also beneﬁ  t from screening and 
treatment (11). In addition, because immigrants with in-
adequate access to healthcare are at risk for being lost to 
follow-up after delivery, perinatal screening offers a good 
opportunity to screen other family members and offer treat-
ment as needed.
Because most pregnant women receive their diagnosis 
during the chronic, asymptomatic stage of Chagas disease, 
screening with 2 sequential serologic tests is the most efﬁ  -
cient strategy for detection of infection (12). PCR and par-
asitologic tests are ineffective for detection because they 
show lower sensitivity during this phase (13). In contrast, 
infected newborns usually have high levels of parasitemia. 
Therefore, microscopic techniques such as microhema-
tocrit and concentration methods in umbilical cord blood 
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Figure 2. Algorithm for screening, diagnosis, and treatment of 
Trypanosoma cruzi congenital infection at Geneva University 
Hospitals, Geneva, Switzerland.Chagas Disease in Latin American Immigrants
have fairly high (>80%) sensitivity (14). PCR is more 
sensitive for detecting Chagas infection in infants than in 
adults; however, few laboratories perform T. cruzi PCR in 
Europe.
Launched in January 2008, a program of systematic 
Chagas disease screening of pregnant women at risk and 
of newborns delivered by infected mothers is under way at 
the Geneva University Hospitals (Figure 2). All pregnant 
women from Mexico and Central and South America are 
screened by serologic testing. Newborns of infected moth-
ers are screened by microscopic examination of cord blood 
after concentration (microhematocrit, Strout’s method) 
and, if negative, by PCR. If PCR is negative, serologic test-
ing is performed when the child is 9 months of age. Blood 
cultures are not performed because of time needed to obtain 
results. Examination of the placenta, which is an unreli-
able screening method, is also not conducted for diagnos-
tic purposes (15). All infected mothers (after completion 
of breast-feeding), newborns, and their siblings are offered 
treatment for this potentially fatal disease. Prenatal and de-
livery care of Latin American immigrants is an opportu-
nity to screen for Chagas disease and its potential vertical 
transmission. This strategy will help address this emergent 
health problem in Europe.
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